StemRIM Past Earnings Performance
Past criteria checks 0/6
StemRIM's earnings have been declining at an average annual rate of -31.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 9.1% per year.
Key information
-31.4%
Earnings growth rate
-29.8%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | -9.1% |
| Return on equity | -25.2% |
| Net Margin | n/a |
| Next Earnings Update | 12 Mar 2025 |
Revenue & Expenses Breakdown
How StemRIM makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Oct 24 | 0 | -2,115 | 646 | 1,484 |
| 31 Jul 24 | 0 | -2,022 | 595 | 1,453 |
| 30 Apr 24 | 0 | -2,131 | 596 | 1,538 |
| 31 Jan 24 | 2,350 | 179 | 607 | 1,560 |
| 31 Oct 23 | 2,350 | 214 | 610 | 1,545 |
| 31 Jul 23 | 2,350 | 168 | 609 | 1,567 |
| 30 Apr 23 | 2,350 | 332 | 556 | 1,479 |
| 31 Jan 23 | 0 | -1,957 | 545 | 1,438 |
| 31 Oct 22 | 0 | -1,971 | 537 | 1,433 |
| 31 Jul 22 | 22 | -1,948 | 549 | 1,421 |
| 30 Apr 22 | 1,212 | -788 | 546 | 1,439 |
| 31 Jan 22 | 1,212 | -813 | 517 | 1,485 |
| 31 Oct 21 | 1,212 | -811 | 473 | 1,521 |
| 31 Jul 21 | 1,400 | -582 | 437 | 1,523 |
| 30 Apr 21 | 1,910 | -501 | 461 | 1,929 |
| 31 Jan 21 | 2,310 | 89 | 437 | 1,762 |
| 31 Oct 20 | 2,310 | 358 | 386 | 1,553 |
| 31 Jul 20 | 2,100 | 347 | 321 | 1,356 |
| 30 Apr 20 | 400 | -662 | 258 | 752 |
| 31 Jul 19 | 100 | -721 | 185 | 640 |
| 31 Jul 18 | 200 | -323 | 122 | 453 |
| 31 Jul 17 | 300 | -123 | 111 | 349 |
Quality Earnings: 4599 is currently unprofitable.
Growing Profit Margin: 4599 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4599 is unprofitable, and losses have increased over the past 5 years at a rate of 31.4% per year.
Accelerating Growth: Unable to compare 4599's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4599 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-36.8%).
Return on Equity
High ROE: 4599 has a negative Return on Equity (-25.19%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 02:52 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
StemRIM is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyoichiro Shigemura | Nomura Securities Co. Ltd. |
| Hiroyuki Matsubara | Nomura Securities Co. Ltd. |